XOPENEX by Hikma is 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3', 5'-adenosine monophosphate (cyclic amp). First approved in 1999.
Drug data last refreshed 13h ago · AI intelligence enriched 2mo ago
XOPENEX is a levalbuterol hydrochloride solution administered via inhalation for the treatment of bronchospasm and reversible obstructive airway disease. As the active R-enantiomer of albuterol, levalbuterol is designed to provide faster symptom relief with potentially reduced tremor compared to racemic albuterol. It is positioned as a rescue inhaler for acute respiratory symptoms in asthma and COPD patients.
Declining revenue trajectory and modest claim volume signal contraction phase; commercial teams likely focused on defend-and-harvest strategies rather than growth.
2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3', 5'-adenosine monophosphate (cyclic AMP). The increase in cyclic AMP is associated with the activation of protein kinase A, which in turn,…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on XOPENEX at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on XOPENEX offers limited growth opportunity and presents a career challenge in a declining, mature product with minimal job openings. This role suits professionals seeking stability in a defend-and-harvest environment or looking to build deep respiratory/rescue inhaler expertise in a commoditized market.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo